Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders
about
Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerationsEfficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorderAquaporin-4 antibodies in patients treated with natalizumab for suspected MS.Higher frequency of brain abnormalities in neuromyelitis optica spectrum disorder patients without primary Sjögren's syndrome.Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response.Neuromyelitis Optica Spectrum Disorder with Tumefactive Demyelination mimicking Multiple Sclerosis: A Rare Case.Stratification of responders towards eculizumab using a structural epitope mapping strategy.Neuro-Immunotherapies: A 30-year Retrospective of an Overwhelming Success and a Brighter Future.Importance of Regular and Maintenance Therapy Adherence in Neuromyelitis Optica (NMO): Lessons from a Repeating Relapse Case.Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study.Tocilizumab, MS, and NMOSD.Cerebral Blood Flow Changes in Multiple Sclerosis and Neuromyelitis Optica and Their Correlations With Clinical Disability.Tolerogenic Dendritic Cells as a Promising Antigen-Specific Therapy in the Treatment of Multiple Sclerosis and Neuromyelitis Optica From Preclinical to Clinical Trials.Treatment strategies for neuromyelitis opticaApheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventionsDiagnosis and Treatment of NMO Spectrum Disorder and MOG-EncephalomyelitisLow-Dose Mycophenolate Mofetil for Treatment of Neuromyelitis Optica Spectrum Disorders: A Prospective Multicenter Study in South China
P2860
Q26765300-A216A428-0953-4B9E-82F4-C10A812B1C56Q33678297-97DD1FCC-62AE-43DF-B5CF-6F88C2A7AB3CQ33808279-90CC9BDB-E678-4E1D-A378-122A0EAE6F57Q37425235-14F3585A-BD02-4956-B766-98C58F41862AQ38750021-FE23C524-E294-4690-B8C2-05014932A042Q41332248-706A919B-CC7A-4AF3-893B-C7DCBFB58A3CQ42364725-7348F0A9-C1B8-49BC-9BEE-472F7B9E32FBQ43077236-0212234F-5BE6-4843-B3D6-DF8E823474D0Q47555447-7C55F683-F1B6-43A5-877A-76B20370AD2DQ48949337-C266BC37-1ECE-4CA4-AB80-C0AFCA239E44Q54450647-5B7E0578-7829-4792-A407-3650A60666D0Q54935884-19607CA8-4F47-4873-A127-E638489E6011Q55258910-421A239A-F90C-4EC6-96F5-E12B794C76AFQ57298520-4516E716-E314-4D1B-AEDC-2286016B25D6Q57821319-E295A956-4DEF-4EF3-BB5E-B97789575052Q58573155-6329AE18-B974-47D2-85AC-7FA4324330C5Q58750166-0DCB4E69-7E37-4B65-B47A-94313AF4B006
P2860
Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders
@ast
Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders
@en
type
label
Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders
@ast
Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders
@en
prefLabel
Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders
@ast
Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders
@en
P2860
P1433
P1476
Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders
@en
P2093
P2860
P2888
P356
10.1007/S13311-015-0400-8
P50
P577
2015-11-23T00:00:00Z